Baidu
map

Ann Oncol:引发非小细胞肺癌患者死亡的并发症

2015-06-03 徐媛媛译 MedSci原创

许多非小细胞肺癌(NSCLC)患者在确诊后的前几年就会死亡,在确诊5年后仍有相当大的死亡数。本研究调查了在长期随访期间不同年龄和疾病阶段的非小细胞患者死亡率和死因的分布。 研究人员收纳了来自荷兰癌症登记处在1989-2008年间确诊为I–III期非小细胞肺癌并于2011年前死亡的72021名患者,年龄在45-89岁。在确诊为非小细胞肺癌后的5个时间段内,计算了死亡比率及死亡原因分布比例。 平均

许多非小细胞肺癌(NSCLC)患者在确诊后的前几年就会死亡,在确诊5年后仍有相当大的死亡数。本研究调查了在长期随访期间不同年龄和疾病阶段的非小细胞患者死亡率和死因的分布。

研究人员收纳了来自荷兰癌症登记处在1989-2008年间确诊为I–III期非小细胞肺癌并于2011年前死亡的72021名患者,年龄在45-89岁。在确诊为非小细胞肺癌后的5个时间段内,计算了死亡比率及死亡原因分布比例。

平均随访9.6年(范围:0-23年)。在确诊后的前六年肺癌成为死亡的主要原因(确诊时为局部疾病在3年内死亡的死于肺癌占80%–85%;确诊时为局部晚期疾病3年死亡的死于肺癌占90%;确诊时为局部疾病4-6年内死亡的死于肺癌占60%–75%;确诊时为局部晚期疾病4-6年内死亡的,在所有死因中肺癌占75%–85%)。此后,肺癌作为死亡原因的比例下降,但仍超过30%。因此,心血管疾病和慢性阻塞性肺疾病(COPD)成为更重要的死亡原因,尤其对年龄> 60岁的患者,心血管疾病死亡风险高达34%,慢性阻塞性肺病死亡风险高达19%。

随着时间的推移,心血管和慢性阻塞性肺病死亡原因的占比增加,尽管在非转移性非小细胞肺癌患者中的死亡原因中,肺癌的绝对占比始终都很高。因此,管理好这些疾病非常有必要。

原始出处

Janssen-Heijnen ML1, van Erning FN2, De Ruysscher DK3, Coebergh JW4, Groen HJ5.Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis.Ann Oncol. 2015 May

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
    2015-08-10 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1990545, encodeId=576f1990545ad, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Jul 16 08:47:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983458, encodeId=cd31198345868, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 03 04:47:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864666, encodeId=333c186466691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 10 06:47:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757656, encodeId=f7f51e5765645, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jan 03 17:47:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059505, encodeId=9693205950561, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Feb 26 18:47:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600805, encodeId=c39e1600805c8, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Jun 05 01:47:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25895, encodeId=005e258955f, content=给临床医生提供了警示, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Thu Jun 04 09:08:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
    2015-06-04 liliweini

    给临床医生提供了警示

    0

相关资讯

Lancet Oncol:治疗手术可切除早期肺癌,立体定向放疗(SABR)比手术疗效更好

背景:可手术治疗的,I期非小细胞肺癌(NSCLC)的标准治疗方法是纵隔淋巴结解剖或取样的肺叶切除术。目前已知,立体定向放疗(SABR)用于不能动手术的I期非小细胞肺癌有良好的前景,但SABR用于可手术治疗的I期NSCLC患者的两个独立、随机、III期临床试验(STARS和ROSEL),由于缓慢的责权发生制提早终止。我们旨在通过这些试验的集中数据评估SABR vs手术的总体生存期。方法:在STARS

N Engl J Med.:AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效

背景:肺癌表皮生长因子受体突变(EGFR-突变肺癌)患者EGFR T790M突变是表皮生长因子受体(EGFR)酪氨酸激酶抑制剂最常见的耐药机制。在临床前模型中,EGFR抑制剂AZD9291已证明对表皮生长因子受体酪氨酸激酶抑制剂-敏化和T790M抵抗突变是有效的。方法:先前EGFR酪氨酸激酶抑制剂治疗后放射记录疾病仍有进展的晚期肺癌患者,以AZD9291  20到24

Cancer:转移性非小细胞肺癌化疗治疗模式

在临床试验中,治疗转移性非小细胞肺癌(NSCLC)的新方法可改善患者生存状况。然而,只有少数患者接受系统性治疗。本文对来自加拿大安大略省的转移性非小细胞肺癌患者的治疗策略和结果进行了分析报道。 通过多个相关数据库数据的筛查,我们确定了2005~2009年间诊断为Ⅳ期非小细胞肺癌患者。本研究收纳了转移性非小细胞肺癌(NSCLC)患者8113例,中位年龄为68岁,39%患有腺癌,14%的患者有鳞状细

Cancer Cell:LKB1失活调控非小细胞肺癌可塑性和药物反应机制

5月1日,国际学术期刊Cancer Cell在线发表了中国科学院上海生命科学研究院生物化学与细胞生物学研究所季红斌研究组的最新研究成果“LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-Small Cell Lung Cancer Plasticity and Therapeutic Response”。该研究深入揭示了LKB1

JTO:肿瘤低代谢预示早期非小细胞肺癌患者更高生存率

功能分子影像是从分子水平在活体研究细胞功能代谢的全新领域,是分子生物学、生物化学、数据图象处理等多学科融合的结果。正电子发射断层扫描(Positron emission tomography, PET)即是功能分子影像的代表,它可显示机体及病灶组织的细胞代谢、增值状况,是非常灵敏的诊断及评价肿瘤生物学特性的先进的分子影像技术。PET能在肿瘤大小改变之前即能检测到其功能代谢异常,能够为临床提供定位、

NEJM:Rociletinib药物在EGFR突变的非小细胞肺癌效应评估

    编码表皮生长因子受体(EGFR)基因的突变的非小细胞肺癌(NSCLC)对批准EGFR抑制剂敏感,但耐药性的发展,在大多数情况下是由T790M EGFR突变介导的。Rociletinib(CO-1686)是一种活性EGFR抑制剂,应用在EGFR突变的NSCLC的有或无T790M临床前模型中。    在这个1-2阶段研究中,我们给予EGFR突变的非小细胞

Baidu
map
Baidu
map
Baidu
map